AC Immune SA
ACIUHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative. At a $246.3M market cap, AC Immune SA ranks as a micro-cap company within healthcare. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Market Cap
$246.3M
Beta
1.65
P/E (TTM)
—
P/E (Fwd)
16.31
EPS (TTM)
$-0.84
EPS (Fwd)
$0.15
ROE
-104.8%
ROA
-23.1%
Cash
$74.8M
Total Debt
$4.3M
Free CF
—
52W Change
44.9%
Annual Financials
Cash vs Debt
AC Immune SA holds $74.8M in cash against $4.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Return on equity stands at -104.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 1.65 means ACIU is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, ACIU has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ACIU.